Dimension Therapeutics, Inc. , a biopharmaceutical company advancing novel, adeno-associated virus gene therapies targeting the liver, a key organ for human metabolism, today announced that it will report financial results for the full year ended December 31, 2016, on Thursday, March 9, 2017. Following distribution of the earnings release via wire services, Dimension Therapeutics will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the Company’s financial results and provide a business update.